Research
Hormonal
Resmetirom, a selective thyroid hormone receptor beta (THRβ) agonist, significantly reduces hepatic steatosis, liver fibrosis, and serum lipid levels (LDL, TG, ApoB) in patients with MASLD, particularly those with fibrosis.
For patients with fatty liver disease who have developed early scarring (fibrosis), Resmetirom is a new medication that targets the liver specifically to burn fat and reduce scarring. It also lowers bad cholesterol (LDL) and triglycerides. Clinical trials show it significantly improves liver health markers.
GoodSupportsHIGH confidence
Resmetirom (MGL-3196) is a liver-targeted selective THRβ agonist. It resulted in significant reduction in hepatic steatosis and serum lipid metabolic products such as LDL, TG and ApoB and improvement in MRI-PDFF among patients with MASLD... Recently, the published phase 3 trials showed that resmetirom significantly improved liver fibrosis and inflammation, and reduced LFC as well as serum LDL-c, ApoB, and TG concentrations [89, 90].
Why this rating
Cites phase 3 trials showing significant improvements.
Source
Advances in management of metabolic dysfunction-associated steatotic liver disease: from mechanisms to therapeutics
Yuxiao Jiang et al. · Lipids in Health and Disease · 2024
DOI 10.1186/s12944-024-02092-2
narrative_reviewCited 28×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 receptor agonists (including semaglutide, liraglutide, dulaglutide, and tirzepatide) significantly reduce hepatic lipid content and improve liver histology (steatosis, inflammation, and fibrosis) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), primarily through weight loss and direct metabolic modulation.Good
- Inhibitors of hepatic lipogenesis (including ACLY, ACC, FAS, SCD1, and DGAT2 inhibitors) reduce liver fat content in MASLD, but some (like ACC inhibitors) may increase serum triglycerides, necessitating combination therapies (e.g., ACC + DGAT2 inhibitors) to mitigate adverse lipid effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →